Clinical Trials Directory

Trials / Unknown

UnknownNCT03695107

Clinical Study on the Effect of PTH on CYP3A4 Activity

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
The Third Xiangya Hospital of Central South University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4 expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit

Conditions

Interventions

TypeNameDescription
DRUGNifedipine controlled released tabletslower blood pressure

Timeline

Start date
2019-10-02
Primary completion
2020-09-10
Completion
2020-09-10
First posted
2018-10-03
Last updated
2019-09-19

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03695107. Inclusion in this directory is not an endorsement.